Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma

被引：5
|
作者：
Wang, Shuai [1 ]
Wu, Xuan [1 ]
Zhao, Jiuzhou [2 ]
Chen, Haiyang [1 ]
Zhang, Zhe [1 ]
Wang, Mingyue [1 ]
Xu, Cong [1 ]
Wang, Yongsen [2 ]
Wang, Lili [1 ]
He, Zhen [1 ]
Wang, Qiming [1 ]
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Dept Internal Med, 127 Dong Ming Rd, Zhengzhou 450008, Henan, Peoples R China
[2] Zhengzhou Univ, Henan Canc Hosp, Dept Mol Pathol, Zhengzhou, Peoples R China
来源：
CLINICAL LUNG CANCER | 2021年 / 22卷 / 03期
基金：
中国国家自然科学基金;
关键词：
Crizotinib; Generation sequencin; Lung large-cell neuroendocrine carcinoma; PLB1-ALK; Sensitivity; ALK-REARRANGEMENT;
D O I：
10.1016/j.cllc.2020.05.026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E366 / E370
页数：5
相关论文
共 50 条
  • [1] PLB1-ALK: A novel head-to-head fusion gene identified by next-generation sequencing in a lung adenocarcinoma patient
    Wang, Bei
    Chen, Rongrong
    Wang, Changxi
    Chen, Huang
    Zhong, Dingrong
    [J]. LUNG CANCER, 2021, 153 : 176 - 178
  • [2] Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non-Small-Cell Lung Cancer
    Peled, Nir
    Palmer, Gary
    Hirsch, Fred R.
    Wynes, Murry W.
    Ilouze, Maya
    Varella-Garcia, Marileila
    Soussan-Gutman, Lior
    Otto, Geoff A.
    Stephens, Philip J.
    Ross, Jeffrey S.
    Cronin, Maureen T.
    Lipson, Doron
    Miller, Vincent A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : E14 - E16
  • [3] Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma
    He, Zhen
    Wu, Xuan
    Ma, Shuxiang
    Zhang, Cuicui
    Zhang, Zhe
    Wang, Shuai
    Yu, Sheng
    Wang, Qiming
    [J]. CLINICAL LUNG CANCER, 2019, 20 (05) : E548 - E551
  • [4] Treatment approach for large-cell neuroendocrine carcinoma of the lung using next-generation sequencing
    Umemura, Shigeki
    Miyoshi, Tomohiro
    Ishii, Genichiro
    Tsuchihara, Katsuya
    [J]. TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S448 - S449
  • [5] A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4-ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib
    Omachi, Naoki
    Shimizu, Shigeki
    Kawaguchi, Tomoya
    Tezuka, Kenji
    Kanazu, Masaki
    Tamiya, Akihiro
    Asami, Kazuhiro
    Okishio, Kyoichi
    Kitaichi, Masanori
    Atagi, Shinji
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (06) : E40 - E42
  • [6] A rare case of large-cell neuroendocrine lung carcinoma sensitive to ALK inhibitors
    Wiedemann, C.
    Kunz, J.
    Kirchner, M.
    Volckmar, A. -L.
    Winter, U.
    Bochtler, T.
    Dietz, S.
    Sueltmann, H.
    Heussel, C. -P.
    Herth, F.
    Grosch, H.
    Bischoff, H.
    Stenzinger, A.
    Thomas, M.
    Christopoulos, P.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 210 - 210
  • [7] Identification of Genomic Aberrations in Large Cell Neuroendocrine Carcinoma of Lung by Targeted Next-Generation Sequencing
    Chun, S.
    Lee, J.
    Jeon, H.
    Kim, D.
    Lee, S.
    Ahn, S.
    Kim, J.
    Jnag, S.
    Jang, S.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 814 - 814
  • [8] Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing
    Xia, Yuxue
    Zhang, Lu
    He, Wenjuan
    Pan, Huaxiong
    Fang, Jun
    Cui, Guohui
    [J]. CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [9] Next-generation sequencing discordant ALK-rearrangement in non-small cell lung carcinoma with ovarian metastases
    Tan, Charles Jeffrey Lay
    Li, Rubi K.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1460 - S1460
  • [10] Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing
    Zhu, Y. C.
    Wang, W. X.
    Xu, C. W.
    Zhang, Q. X.
    Du, K. Q.
    Chen, G.
    Lv, T. F.
    Song, Y.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (12) : 2392 - 2393
12345